Keyphrases
Venous Thromboembolism
100%
Multiple Myeloma
100%
Chronic Liver Disease
100%
Hemorrhage Risk
71%
Anticoagulation
57%
Increased Mortality
57%
University of Washington
50%
Coagulation Profile
50%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
50%
Splanchnic Vein Thrombosis
50%
Clinical Investigator
50%
Hospitalization
50%
Abiraterone
50%
Enzalutamide
50%
Direct Oral Anticoagulants
50%
Pulmonary Embolism
50%
Cirrhosis
50%
Deep Vein Thrombosis
50%
Population-based
50%
Graft-versus-host Disease (GvHD)
50%
Warfarin Therapy
50%
Statins
50%
International Normalized Ratio
50%
Resectable Pancreatic Cancer
50%
Population-based Retrospective Cohort Study
50%
Philadelphia-negative Myeloproliferative Neoplasms
50%
Confidence Interval
42%
Primary Myelofibrosis
40%
Essential Thrombocythemia
40%
Prognostic Factors
35%
Warfarin
35%
Isocitrate Dehydrogenase 1 (IDH1)
30%
Polycythemia Vera
30%
Adjusted Hazard Ratio
29%
Anticoagulant Therapy
28%
Androgen Receptor Antagonist
27%
Hematologist
25%
Evidence-based Guidelines
25%
Transfusion Medicine
25%
Young Female
25%
Clinical Effect
25%
Department of Medicine
25%
Health Outcomes
25%
Coagulation Factors
25%
Thrombocytopenia
25%
Veterans Hospital
25%
Cryoprecipitate
25%
Hemodynamically Unstable
25%
Hematology
25%
Cleveland Clinic
25%
Medicine and Dentistry
Prognostic Factor
55%
Direct Oral Anticoagulant
50%
Liver Cirrhosis
50%
Venous Thromboembolism
50%
Deep Vein Thrombosis
50%
Pulmonary Embolism
50%
Multiple Myeloma
50%
Myeloproliferative Neoplasm
50%
Prognostication
50%
Phlebothrombosis
50%
Pancreas Cancer
50%
Philadelphia 1 Chromosome
50%
Myeloid metaplasia
40%
Essential Thrombocythaemia
40%
Bleeding
38%
Anticoagulation
32%
Polycythemia vera
30%
Anticoagulant Therapy
28%
Thrombosis
26%
Portal Hypertension
25%
Platelet
25%
Nonalcoholic Fatty Liver
25%
Child-Pugh Score
25%
Hepatic Encephalopathy
25%
Thrombocytopenia
25%
Partial Thromboplastin Time
25%
Prothrombin Time
25%
Fibrinogen
25%
Esophageal Varices
25%
Myelofibrosis
20%
Disease
20%
ASXL1
20%
Proportional Hazards Model
19%
Hazard Ratio
16%
Lenalidomide
16%
Pancreas Adenocarcinoma
14%
Veterans Health
12%
Myeloma
11%
Chromosome Aberration
10%
Janus Kinase
10%
Hydroxyurea
10%
Phlebotomy
10%
Leukocytosis
10%
Prospective Study
10%
Risk Stratification
10%
Splenomegaly
10%
Splanchnic Blood Flow
7%
International Classification of Diseases
7%
Cancer
7%
Thromboprophylaxis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Chronic Liver Disease
100%
Bleeding
75%
Venous Thromboembolism
50%
Enzalutamide
50%
Acute Graft Versus Host Disease
50%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
50%
Abiraterone
50%
Warfarin
50%
Prostate Cancer
50%
Cohort Study
50%
Chronic Graft Versus Host Disease
50%
Graft Versus Host Reaction
37%
Androgen Receptor
27%
Clinical Research
25%
Blood Clotting Factor
25%
Adverse Event
25%
Blood Clotting Disorder
25%
Clinical Trial
25%
Myeloma
17%
Lenalidomide
16%
Thrombosis
16%
International Classification of Diseases
12%
Comorbidity
10%
